E
HARP

Ergoteles’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Ergoteles’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,005
Closed -$68K – 2057
2022
Q3 		$68K Sell
7,005
-2,185
-24% -$40.8K ﹤0.01% 1419
2022
Q2 		$176K Buy
+9,190
New +$238K 0.01% 1373

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ergoteles's HARP Position: Q4 2022 in Review

Ergoteles sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2022, closing a stake of 7,005 shares — an estimated $68K sold.

Ergoteles first reported a position in HARP in Q2 2022 and held it in 2 quarters. The position peaked at $176K in Q2 2022. 49 funds tracked by Wall St. Rank hold HARP as of Q4 2022.

  • Ergoteles reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 7,005 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $68K.
  • Ergoteles first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Harpoon Therapeutics, Inc. Common Stock position peaked at $176K in Q2 2022.
  • 49 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.